The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer.

IF 12.5 1区 医学 Q1 ONCOLOGY
Shayna Thomas-Jardin,Shruthy Suresh,Ariana Arce,Nicole Novaresi,Qing Deng,Emily Stein,Lisa Thomas,Cheryl Lewis,Chul Ahn,Bret M Evers,Esra A Akbay,Maria E Salvatierra,Wei Lu,Khaja Khan,Luisa M Solis Soto,Ignacio I Wistuba,John D Minna,Kathryn A O'Donnell
{"title":"The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer.","authors":"Shayna Thomas-Jardin,Shruthy Suresh,Ariana Arce,Nicole Novaresi,Qing Deng,Emily Stein,Lisa Thomas,Cheryl Lewis,Chul Ahn,Bret M Evers,Esra A Akbay,Maria E Salvatierra,Wei Lu,Khaja Khan,Luisa M Solis Soto,Ignacio I Wistuba,John D Minna,Kathryn A O'Donnell","doi":"10.1158/0008-5472.can-24-3844","DOIUrl":null,"url":null,"abstract":"The integrated stress response (ISR) is an adaptive pathway hijacked by cancer cells to survive cellular stresses in the tumor microenvironment. ISR activation potently induces PD-L1, leading to suppression of anti-tumor immunity. Here, we sought to uncover additional immune checkpoint proteins regulated by the ISR to elucidate mechanisms of tumor immune escape. ISR coordinately induced CD155 and PD-L1, enhancing translation of both immune checkpoint proteins through bypass of inhibitory upstream open reading frames in their 5' UTRs. Analysis of primary human lung tumors identified a significant correlation between expression of PD-L1 and CD155. ISR activation accelerated tumorigenesis and inhibited T cell function, which could be overcome by combining PD-1 and TIGIT blockade with the ISR inhibitor ISRIB. This study uncovers a mechanism by which two immune checkpoint proteins are coordinately regulated and suggests a therapeutic strategy for lung cancer patients.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"115 1","pages":""},"PeriodicalIF":12.5000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/0008-5472.can-24-3844","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The integrated stress response (ISR) is an adaptive pathway hijacked by cancer cells to survive cellular stresses in the tumor microenvironment. ISR activation potently induces PD-L1, leading to suppression of anti-tumor immunity. Here, we sought to uncover additional immune checkpoint proteins regulated by the ISR to elucidate mechanisms of tumor immune escape. ISR coordinately induced CD155 and PD-L1, enhancing translation of both immune checkpoint proteins through bypass of inhibitory upstream open reading frames in their 5' UTRs. Analysis of primary human lung tumors identified a significant correlation between expression of PD-L1 and CD155. ISR activation accelerated tumorigenesis and inhibited T cell function, which could be overcome by combining PD-1 and TIGIT blockade with the ISR inhibitor ISRIB. This study uncovers a mechanism by which two immune checkpoint proteins are coordinately regulated and suggests a therapeutic strategy for lung cancer patients.
综合应激反应途径协调肺癌中多个免疫检查点的翻译控制。
综合应激反应(integrated stress response, ISR)是癌细胞在肿瘤微环境中劫持细胞应激生存的一种适应性通路。ISR激活可有效诱导PD-L1,从而抑制抗肿瘤免疫。在这里,我们试图揭示由ISR调节的其他免疫检查点蛋白,以阐明肿瘤免疫逃逸的机制。ISR协调诱导CD155和PD-L1,通过绕过5' utr中上游的限制性开放阅读框,增强这两种免疫检查点蛋白的翻译。对原发人肺肿瘤的分析发现PD-L1和CD155的表达有显著相关性。ISR激活加速肿瘤发生并抑制T细胞功能,这可以通过PD-1和TIGIT阻断与ISR抑制剂ISRIB联合来克服。这项研究揭示了两种免疫检查点蛋白协调调节的机制,并为肺癌患者提供了一种治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer research
Cancer research 医学-肿瘤学
CiteScore
16.10
自引率
0.90%
发文量
7677
审稿时长
2.5 months
期刊介绍: Cancer Research, published by the American Association for Cancer Research (AACR), is a journal that focuses on impactful original studies, reviews, and opinion pieces relevant to the broad cancer research community. Manuscripts that present conceptual or technological advances leading to insights into cancer biology are particularly sought after. The journal also places emphasis on convergence science, which involves bridging multiple distinct areas of cancer research. With primary subsections including Cancer Biology, Cancer Immunology, Cancer Metabolism and Molecular Mechanisms, Translational Cancer Biology, Cancer Landscapes, and Convergence Science, Cancer Research has a comprehensive scope. It is published twice a month and has one volume per year, with a print ISSN of 0008-5472 and an online ISSN of 1538-7445. Cancer Research is abstracted and/or indexed in various databases and platforms, including BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信